CD274 and neoplasm: Over all, immunotherapy targeting the PD-L1/PD-1 pathway has a dual character, prescription opioids should be used with caution for tumor patients treated with PD-L1/PD-1 inhibitor and we should further study to optimize immunotherapy targeting the PD-L1/PD-1 pathway or develop combination therapies with PD-L1/PD-1 blockade to improve treatment efficiency and reduce side effects.